SCHEMBL3987359

SCHEMBL3987359

O=C(Nc1cccc(F)c1)Nc1cc(CO)cc(Nc2c3ccccc3nc3ccccc23)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 6/20 0.64
TOP2B Q02880 6/20 0.64
KDM4E B2RXH2 1/20 0.51
MEN1 O00255 1/20 0.51
NPC1 O15118 1/20 0.51
ALDH1A1 P00352 1/20 0.51
LMNA P02545 1/20 0.51
GLA P06280 1/20 0.51
GAA P10253 1/20 0.51
MAPT P10636 1/20 0.51
MAPK1 P28482 1/20 0.51
HTT P42858 1/20 0.51
KMT2A Q03164 1/20 0.51
MCL1 Q07820 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
MTOR P42345 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
HDAC3 O15379 1/20 0.46
ACHE P22303 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3983933 0.92 TOP2A (0.67) TOP2ATOP2BKDM4ELMNAMAPT
SCHEMBL3987121 0.84 TOP2A (0.67) TOP2ATOP2BMEN1MAPTKMT2A
SCHEMBL3985990 0.82 TOP2A (0.52) TOP2ATOP2B
SCHEMBL9300052 0.81 TOP2A (0.73) TOP2ATOP2BKDM4EMEN1NPC1
SCHEMBL3983138 0.81 TOP2A (0.53) TOP2ATOP2B
SCHEMBL3983034 0.79 TOP2A (0.77) TOP2ATOP2BKDM4ELMNAMAPT
SCHEMBL9302060 0.78 TOP2A (0.76) TOP2ATOP2BKDM4ELMNAMAPT
SCHEMBL4904565 0.78 TOP2A (0.59) TOP2ATOP2BKDM4ELMNAMAPT
SCHEMBL3984609 0.77 TOP2A (0.74) TOP2ATOP2BKDM4ELMNAMAPT
SCHEMBL7561273 0.77 TOP2A (0.70) TOP2ATOP2BKDM4EMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1380574-B1 9-aminoacridine derivates and process for the preparation thereof SAMJIN PHARM CO LTD (KR) 2009-05-20 EP disclosed
EP-1380574-A1 9-aminoacridine derivates and process for the preparation thereof Samjin Pharmaceutical Co., Ltd. (KR) 2004-01-14 EP disclosed
US-6620936-B2 Antitumor agents, topoisomerase inhibitors, notoxic SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2003-09-16 US disclosed
US-20020111491-A1 9-aminoacridine derivatives and process for the preparation thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2002-08-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020111491-A1 9-aminoacridine derivatives and process for the preparation thereof ALKBH1, ADCY9, CCR9 TOP2A 1105/4885TOP2B 841/4885KDM4E 1567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.